论文部分内容阅读
目的探讨应用胸腺素α1治疗慢性重型乙型病毒性肝炎的临床疗效。方法将我院收治的慢性重型乙型病毒性肝炎患者82例随机分为对照组和观察组,2组患者在入院后行西药常规治疗,观察组在此基础上加用胸腺素α1,治疗8周后对2组患者肝功能进行对比,随访1年观察其存活率。结果治疗8周后,观察组和对照组的肝功能均有所改善,观察组改善情况显著高于对照组(P<0.05);随访1年,观察组患者的存活率显著高于对照组(P<0.05)。结论应用胸腺素α1治疗慢性重型乙型病毒性肝炎,能够显著改善肝功能,提高1年存活率,对患者具有重要的现实意义,值得临床推广应用。
Objective To investigate the clinical efficacy of thymosin α1 in the treatment of chronic severe hepatitis B virus. Methods Eighty-two patients with chronic severe hepatitis B admitted to our hospital were randomly divided into control group and observation group. Two groups of patients were treated routinely with western medicine after admission. The observation group was treated with thymosin α1, Week after 2 groups of patients with liver function were compared, followed up for 1 year to observe the survival rate. Results After 8 weeks of treatment, the liver function of the observation group and the control group were improved, and the improvement in the observation group was significantly higher than that of the control group (P <0.05). The survival rate of the observation group was significantly higher than that of the control group P <0.05). Conclusion The application of thymosin α1 in the treatment of chronic severe hepatitis B can significantly improve the liver function and increase the one-year survival rate, which is of great practical significance to patients and worthy of clinical application.